NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
| Autor: | Nicoleta C. Voian, Allison W. Kurian, Tuya Pal, Meagan Farmer, Georgia L. Wiesner, Susan Darlow, Judy Garber, Lisa Madlensky, Kristen M. Shannon, Gwen Reiser, Robert Pilarski, Jennifer K. Litton, Kenneth Offit, Seema A. Khan, Elizabeth M. Swisher, Noah D. Kauff, Mary A. Dwyer, Mary B. Daly, Michael Berry, Saundra S. Buys, Sofia D. Merajver, Susan Hatters Friedman, Shaveta Vinayak, Catherine Klein, Myra J. Wick, Wendy Kohlmann, Jeffrey N. Weitzel |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Genetic counseling MEDLINE Genetic Counseling Risk Assessment 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Genetic Testing Risk management Genetic testing Gynecology medicine.diagnostic_test business.industry medicine.disease 030104 developmental biology Increased risk Hereditary Cancer Syndromes 030220 oncology & carcinogenesis Mutation Practice Guidelines as Topic Hereditary Breast and Ovarian Cancer Syndrome Female business Risk assessment Ovarian cancer |
| Zdroj: | Journal of the National Comprehensive Cancer Network : JNCCN. 15(1) |
| ISSN: | 1540-1413 |
| Popis: | The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding risk management for carriers of moderately penetrant genetic mutations associated with breast and/or ovarian cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|